Published in J Virol on May 01, 2003
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother (2009) 1.60
Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother (2004) 1.26
Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol (2013) 1.15
Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol (2010) 1.03
Cell fusion activities of Hantaan virus envelope glycoproteins. J Virol (2004) 1.01
Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother (2005) 0.96
Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol (2013) 0.93
Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection. J Clin Invest (2014) 0.92
Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol (2004) 0.91
Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function. Virol J (2006) 0.91
Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses (2013) 0.89
Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease. Virol J (2010) 0.88
Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol (2015) 0.88
Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Adv Drug Deliv Rev (2014) 0.87
(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection. J Med Chem (2012) 0.86
A fluorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct screening platform. Anal Biochem (2010) 0.85
A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus. Virol J (2013) 0.85
Targeting RSV with vaccines and small molecule drugs. Infect Disord Drug Targets (2012) 0.81
Antiviral drugs specific for coronaviruses in preclinical development. Curr Opin Virol (2014) 0.80
GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process. Antimicrob Agents Chemother (2015) 0.78
Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. ACS Med Chem Lett (2015) 0.77
Blocking Respiratory Syncytial Virus Entry: A Story with Twists. DNA Cell Biol (2015) 0.77
Structure-guided design of small-molecule therapeutics against RSV disease. Expert Opin Drug Discov (2016) 0.77
Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection. Viruses (2015) 0.76
Engineering and expression of a RhoA peptide against respiratory syncytial virus infection in plants. Planta (2015) 0.76
A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading. Antimicrob Agents Chemother (2017) 0.75
A network flow approach to predict protein targets and flavonoid backbones to treat respiratory syncytial virus infection. Biomed Res Int (2015) 0.75
Creating an artificial tail-anchor as a novel strategy to enhance the potency of peptide-based HIV fusion inhibitors. J Virol (2016) 0.75
Repurposing staples for viruses: applying peptide design to RSV prophylaxis. J Clin Invest (2014) 0.75
Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors. ACS Med Chem Lett (2016) 0.75
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun (2017) 0.75
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem (2000) 19.03
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A (1994) 8.48
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A (1992) 5.88
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med (2000) 5.73
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol (2000) 5.71
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med (1993) 5.67
Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol (1998) 5.62
Paramyxovirus fusion: a hypothesis for changes. Virology (1993) 4.98
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol (1998) 4.48
Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell (1999) 4.17
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 3.88
Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology (1995) 3.87
Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 3.77
Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J (2001) 3.76
Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci U S A (1997) 3.57
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A (1997) 3.49
Respiratory syncytial virus infection in adults. Clin Microbiol Rev (2000) 3.16
Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A (1996) 3.07
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
HIV-1 membrane fusion: targets of opportunity. J Cell Biol (2000) 2.84
Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol (2000) 2.75
Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci U S A (2000) 2.58
The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion. Structure (2001) 2.41
Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol (2001) 2.38
Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A (2001) 2.04
The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol (2000) 2.04
Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology (1999) 2.03
Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology (1996) 1.95
Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology (2000) 1.87
Studies on the fusion peptide of a paramyxovirus fusion glycoprotein: roles of conserved residues in cell fusion. J Virol (1992) 1.76
Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion. Virology (1994) 1.72
Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother (1986) 1.72
Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis (1990) 1.66
Mutations in the fusion peptide and heptad repeat regions of the Newcastle disease virus fusion protein block fusion. J Virol (1994) 1.63
Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. Proc Natl Acad Sci U S A (1997) 1.61
Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J Biol Chem (2001) 1.55
The paramyxovirus SV5 small hydrophobic (SH) protein is not essential for virus growth in tissue culture cells. Virology (1998) 1.46
Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol (1991) 1.42
A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. J Virol Methods (2001) 1.35
Analysis of a peptide inhibitor of paramyxovirus (NDV) fusion using biological assays, NMR, and molecular modeling. Virology (1997) 1.33
Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro. J Virol (1998) 1.29
The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil. J Virol (2000) 1.29
Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J Gen Virol (2000) 1.28
Characteristics of fusion of respiratory syncytial virus with HEp-2 cells as measured by R18 fluorescence dequenching assay. J Virol (1991) 1.22
Modelling the structure of the fusion protein from human respiratory syncytial virus. Protein Eng (2002) 1.17
RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol (2001) 1.15
Heptad-repeat regions of respiratory syncytial virus F1 protein form a six-membered coiled-coil complex. Biochemistry (2000) 1.13
Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. J Gen Virol (2001) 1.12
Synergism between recombinant human interferon and nucleoside antiviral agents against herpes simplex virus: examination with an automated microtiter plate assay. J Infect Dis (1985) 1.01
RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother (2002) 0.97
CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res (1998) 0.89
Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Drug Discov Today (2000) 0.82
Phage RNA polymerase vectors that allow efficient gene expression in both prokaryotic and eukaryotic cells. Gene (1995) 0.80
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 2.71
Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother (2006) 2.41
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother (2008) 1.79
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother (2005) 1.63
Current status and challenges of antiretroviral research and therapy. Antiviral Res (2009) 1.52
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos (2002) 1.36
Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One (2013) 1.29
Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. J Mol Biol (2010) 1.23
Novel targets for HIV therapy. Antiviral Res (2008) 1.15
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother (2006) 1.14
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother (2006) 1.14
GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res (2008) 1.10
Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother (2007) 1.05
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther (2014) 1.00
Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors. Bioorg Med Chem (2008) 1.00
Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring. J Mol Biol (2006) 1.00
Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol (2008) 0.97
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem (2015) 0.97
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2012) 0.97
In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile. Antimicrob Agents Chemother (2011) 0.96
Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother (2005) 0.96
Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett (2012) 0.92
Generation of endostatin by matrix metalloproteinase and cathepsin from human limbocorneal epithelial cells cultivated on amniotic membrane. Invest Ophthalmol Vis Sci (2007) 0.91
Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent. Antimicrob Agents Chemother (2007) 0.90
Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs. Bioorg Med Chem Lett (2008) 0.86
Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors. Antivir Ther (2014) 0.84
A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. Eur J Med Chem (2011) 0.84
Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorg Med Chem Lett (2011) 0.84
Synthesis and significant cytostatic activity of 7-hetaryl-7-deazaadenosines. J Med Chem (2011) 0.84
Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog Retin Eye Res (2006) 0.83
Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother (2013) 0.83
Role of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191. Antimicrob Agents Chemother (2011) 0.83
Companions reverse stressor-induced decreases in neurogenesis and cocaine conditioning possibly by restoring BDNF and NGF levels in dentate gyrus. Psychoneuroendocrinology (2012) 0.83
Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor. Bioorg Med Chem Lett (2007) 0.82
GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system. Antimicrob Agents Chemother (2011) 0.81
6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents. J Med Chem (2010) 0.81
Human respiratory syncytial virus Memphis 37 grown in HEp-2 cells causes more severe disease in lambs than virus grown in Vero cells. Viruses (2013) 0.80
Highly potent HCV NS4B inhibitors with activity against multiple genotypes. J Med Chem (2014) 0.80
Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorg Med Chem (2010) 0.80
Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. J Med Chem (2010) 0.79
Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates. Bioorg Med Chem Lett (2007) 0.79
A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet Genomics (2015) 0.78
Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374. J Virol (2012) 0.78
In vitro antiangiogenic activity in ex vivo expanded human limbocorneal epithelial cells cultivated on human amniotic membrane. Invest Ophthalmol Vis Sci (2004) 0.78
Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C. Antimicrob Agents Chemother (2013) 0.78
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events. J Infect Dis (2007) 0.78
Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells. J Nat Prod (2014) 0.78
Abyssomicin 2 reactivates latent HIV-1 by a PKC- and HDAC-independent mechanism. Org Lett (2015) 0.77
Odors from proximal species reverse the stress-decreased neurogenesis via main olfactory processing. Behav Brain Res (2011) 0.77
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs. Bioorg Med Chem (2007) 0.77
Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine. Biochem Biophys Res Commun (2004) 0.77
Synthesis and anti-HIV activity of cyclic pyrimidine phosphonomethoxy nucleosides and their prodrugs: a comparison of phosphonates and corresponding nucleosides. Nucleosides Nucleotides Nucleic Acids (2007) 0.76
Synthesis and anti-HIV activity of 2'-fluorine modified nucleoside phosphonates: analogs of GS-9148. Bioorg Med Chem Lett (2007) 0.76
Mutations in adenosine deaminase-like (ADAL) protein confer resistance to the antiproliferative agents N6-cyclopropyl-PMEDAP and GS-9219. Anticancer Res (2013) 0.75